Gary Richardson

7.4k total citations · 2 hit papers
110 papers, 3.8k citations indexed

About

Gary Richardson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gary Richardson has authored 110 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 19 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gary Richardson's work include Lung Cancer Treatments and Mutations (24 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Colorectal Cancer Treatments and Studies (13 papers). Gary Richardson is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Colorectal Cancer Treatments and Studies (13 papers). Gary Richardson collaborates with scholars based in Australia, United States and United Kingdom. Gary Richardson's co-authors include Salvatore Siena, Yves Humblet, Joan Maurel, Jean–Luc Van Laethem, Bart Neyns, Marc Peeters, Eric Van Cutsem, Alain Hendlisz, Jean-Luc Canon and Rafael G. Amado and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Gary Richardson

104 papers receiving 3.7k citations

Hit Papers

Open-Label Phase III Trial of Panitumumab Plus Best Suppo... 2007 2026 2013 2019 2007 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
    2007 1.5k citations Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology profile →
  2. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
    2012 420 citations Allan Lipton, Karim Fizazi et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Richardson Australia 19 2.6k 1.2k 734 478 475 110 3.8k
Tom Børge Johannesen Norway 26 2.1k 0.8× 1.0k 0.8× 673 0.9× 671 1.4× 379 0.8× 89 3.8k
Shenhong Wu United States 35 2.9k 1.1× 1.7k 1.4× 1.4k 2.0× 424 0.9× 430 0.9× 96 5.5k
Jean‐François Morère France 31 2.5k 1.0× 1.3k 1.1× 666 0.9× 498 1.0× 753 1.6× 216 4.0k
Mary Cabiddu Italy 34 2.5k 0.9× 1.3k 1.1× 649 0.9× 887 1.9× 458 1.0× 78 3.9k
Karen Borgonovo Italy 33 2.7k 1.0× 1.5k 1.2× 545 0.7× 667 1.4× 618 1.3× 83 3.8k
Smitha Krishnamurthi United States 25 2.2k 0.8× 939 0.8× 834 1.1× 487 1.0× 493 1.0× 126 3.3k
Rodolfo Passalacqua Italy 28 2.1k 0.8× 1.3k 1.0× 438 0.6× 948 2.0× 509 1.1× 140 3.7k
Ben Tran Australia 14 2.7k 1.0× 994 0.8× 405 0.6× 679 1.4× 430 0.9× 61 4.0k
Ralph Levitt United States 27 2.1k 0.8× 892 0.7× 670 0.9× 682 1.4× 407 0.9× 67 3.6k
Bernhard C. Pestalozzi Switzerland 35 2.9k 1.1× 1.7k 1.3× 598 0.8× 1.1k 2.3× 396 0.8× 107 4.6k

Countries citing papers authored by Gary Richardson

Since Specialization
Citations

This map shows the geographic impact of Gary Richardson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Richardson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Richardson more than expected).

Fields of papers citing papers by Gary Richardson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Richardson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Richardson. The network helps show where Gary Richardson may publish in the future.

Co-authorship network of co-authors of Gary Richardson

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Richardson. A scholar is included among the top collaborators of Gary Richardson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Richardson. Gary Richardson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pham, Jonathan, Tiffany Lin, Eldho Paul, et al.. (2025). Disparities in Timeliness and Guideline‐Concordant Treatment is Associated With Excess Mortality in Public Versus Private Lung Cancer Patients. Asia-Pacific Journal of Clinical Oncology. 22(1). 88–98.
2.
3.
Lemech, Charlotte, Rasha Cosman, Ganessan Kichenadasse, et al.. (2025). First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.. Journal of Clinical Oncology. 43(16_suppl). 2591–2591. 1 indexed citations
4.
Coward, Jermaine, Ganessan Kichenadasse, John Park, et al.. (2024). Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15010–e15010.
5.
Zhou, Caicun, Akira Ono, Hidetoshi Hayashi, et al.. (2024). 635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC. Annals of Oncology. 35. S1638–S1639. 1 indexed citations
6.
Kichenadasse, Ganessan, Gary Richardson, Samantha Bowyer, et al.. (2024). P3.12D.09 Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S350–S350.
7.
Paz‐Ares, Luis, Rémi Veillon, Margarita Majem, et al.. (2024). 7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC. ESMO Open. 9. 102586–102586. 2 indexed citations
8.
Richardson, Gary, Raed Moh’d Taiseer Al-Rajabi, Dipesh Uprety, et al.. (2023). A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors. Cancers. 15(9). 2553–2553. 2 indexed citations
9.
Richardson, Gary, Vladimir Andelkovic, Ganessan Kichenadasse, et al.. (2023). 88TiP A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling. Annals of Oncology. 34. S1501–S1501.
10.
Kanjanapan, Yada, Sheau Wen Lok, Peter Gibbs, et al.. (2020). Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. Breast Cancer Research and Treatment. 184(1). 87–95. 3 indexed citations
11.
Kissane, David W., Irene Bobevski, Joanne Brooker, et al.. (2017). Exploratory examination of the utility of demoralization as a diagnostic specifier for adjustment disorder and major depression. General Hospital Psychiatry. 46. 20–24. 17 indexed citations
12.
Gordon, Alan, Adi Jaffe, A. Thomas McLellan, et al.. (2017). How Should Remote Clinical Monitoring Be Used to Treat Alcohol Use Disorders?: Initial Findings From an Expert Round Table Discussion. Journal of Addiction Medicine. 11(2). 145–153. 12 indexed citations
13.
Meniawy, Tarek, Gary Richardson, Amanda Townsend, et al.. (2017). Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). Annals of Oncology. 28. v130–v130. 2 indexed citations
14.
Parisot, John P., Heather Thorne, Andrew Fellowes, et al.. (2015). “Cancer 2015”: A Prospective, Population-Based Cancer Cohort—Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. Journal of Personalized Medicine. 5(4). 354–369. 8 indexed citations
15.
Lipton, Allan, Karim Fizazi, Alison Stopeck, et al.. (2012). Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 48(16). 3082–3092. 420 indexed citations breakdown →
16.
Siena, Salvatore, Yves Humblet, Eric Van Cutsem, et al.. (2006). Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a phase 3 randomized controlled trial. Annals of Oncology. 17. 249–249. 2 indexed citations
17.
Prince, H. Miles, Dominic Wall, Danny Rischin, et al.. (2002). CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy. 4(2). 147–155. 7 indexed citations
18.
Johnson, Bruce E., et al.. (1997). A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy. American Journal of Respiratory and Critical Care Medicine. 156(5). 1669–1678. 52 indexed citations
19.
Shapiro, Jeremy, et al.. (1996). PREVENTION OF INFECTION IN A PATIENT WITH CHRONIC IDIOPATHIC NEUTROPENIA UNDERGOING CORONARY BYPASS SURGERY WITH PERI‐OPERATIVE G‐CSF. Australian and New Zealand Journal of Surgery. 66(12). 841–842. 2 indexed citations
20.
Richardson, Gary & Dan L. Longo. (1991). Multiple cavitating pulmonary nodules in Hodgkin's disease. Cancer. 68(5). 930–933. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tom Børge Johannesen Breakdown of academic impact, for papers by Shenhong Wu Breakdown of academic impact, for papers by Jean‐François Morère Breakdown of academic impact, for papers by Mary Cabiddu Breakdown of academic impact, for papers by Karen Borgonovo Breakdown of academic impact, for papers by Smitha Krishnamurthi Breakdown of academic impact, for papers by Rodolfo Passalacqua Breakdown of academic impact, for papers by Ben Tran Breakdown of academic impact, for papers by Ralph Levitt Breakdown of academic impact, for papers by Bernhard C. Pestalozzi
Rankless by CCL
2026